TY - JOUR AU - Bray, F. PY - 2018 DA - 2018// TI - Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries JO - CA Cancer J Clin VL - 68 UR - https://doi.org/10.3322/caac.21492 DO - 10.3322/caac.21492 ID - Bray2018 ER - TY - JOUR AU - Akram, M. AU - Iqbal, M. AU - Daniyal, M. AU - Khan, A. U. PY - 2017 DA - 2017// TI - Awareness and current knowledge of breast cancer JO - Biol Res VL - 50 UR - https://doi.org/10.1186/s40659-017-0140-9 DO - 10.1186/s40659-017-0140-9 ID - Akram2017 ER - TY - JOUR AU - Caplan, L. PY - 2014 DA - 2014// TI - Delay in breast cancer: implications for stage at diagnosis and survival JO - Front Public Health VL - 2 UR - https://doi.org/10.3389/fpubh.2014.00087 DO - 10.3389/fpubh.2014.00087 ID - Caplan2014 ER - TY - JOUR AU - Azamjah, N. AU - Soltan-Zadeh, Y. AU - Zayeri, F. PY - 2019 DA - 2019// TI - Global trend of breast cancer mortality rate: a 25-year study JO - Asian Pac J Cancer Prev VL - 20 UR - https://doi.org/10.31557/APJCP.2019.20.7.2015 DO - 10.31557/APJCP.2019.20.7.2015 ID - Azamjah2019 ER - TY - JOUR AU - Tang, Y. AU - Wang, Y. AU - Kiani, M. F. AU - Wang, B. PY - 2016 DA - 2016// TI - Classification, treatment strategy, and associated drug resistance in breast cancer JO - Clin Breast Cancer VL - 16 UR - https://doi.org/10.1016/j.clbc.2016.05.012 DO - 10.1016/j.clbc.2016.05.012 ID - Tang2016 ER - TY - JOUR AU - Hanker, A. B. AU - Sudhan, D. R. AU - Arteaga, C. L. PY - 2020 DA - 2020// TI - Overcoming endocrine resistance in breast cancer JO - Cancer Cell VL - 37 UR - https://doi.org/10.1016/j.ccell.2020.03.009 DO - 10.1016/j.ccell.2020.03.009 ID - Hanker2020 ER - TY - JOUR AU - Spek, Y. M. AU - Kroep, J. R. AU - Tollenaar, R. AU - Mesker, W. E. PY - 2020 DA - 2020// TI - Chemotherapy resistance and stromal targets in breast cancer treatment: a review JO - Mol Biol Rep VL - 47 UR - https://doi.org/10.1007/s11033-020-05853-1 DO - 10.1007/s11033-020-05853-1 ID - Spek2020 ER - TY - JOUR AU - Ju, J. AU - Zhu, A. -. J. AU - Yuan, P. PY - 2018 DA - 2018// TI - Progress in targeted therapy for breast cancer JO - Chronic Dis Transl Med VL - 4 UR - https://doi.org/10.1016/j.cdtm.2018.04.002 DO - 10.1016/j.cdtm.2018.04.002 ID - Ju2018 ER - TY - JOUR AU - Banin Hirata, B. K. PY - 2014 DA - 2014// TI - Molecular markers for breast cancer: prediction on tumor behavior JO - Dis Mark VL - 2014 UR - https://doi.org/10.1155/2014/513158 DO - 10.1155/2014/513158 ID - Banin Hirata2014 ER - TY - JOUR AU - Pasculli, B. AU - Barbano, R. AU - Parrella, P. PY - 2018 DA - 2018// TI - Epigenetics of breast cancer: biology and clinical implication in the era of precision medicine JO - Semin Cancer Biol VL - 51 UR - https://doi.org/10.1016/j.semcancer.2018.01.007 DO - 10.1016/j.semcancer.2018.01.007 ID - Pasculli2018 ER - TY - JOUR AU - Audia, J. E. AU - Campbell, R. M. PY - 2016 DA - 2016// TI - Histone modifications and cancer JO - Cold Spring Harb Perspect Biol VL - 8 UR - https://doi.org/10.1101/cshperspect.a019521 DO - 10.1101/cshperspect.a019521 ID - Audia2016 ER - TY - JOUR AU - Cerbo, V. AU - Schneider, R. PY - 2013 DA - 2013// TI - Cancers with wrong HATs: the impact of acetylation JO - Brief Funct Genomics VL - 12 UR - https://doi.org/10.1093/bfgp/els065 DO - 10.1093/bfgp/els065 ID - Cerbo2013 ER - TY - JOUR AU - Herceg, Z. AU - Ushijima, T. PY - 2010 DA - 2010// TI - Introduction: epigenetics and cancer JO - Adv Genet VL - 70 UR - https://doi.org/10.1016/b978-0-12-380866-0.60001-0 DO - 10.1016/b978-0-12-380866-0.60001-0 ID - Herceg2010 ER - TY - JOUR AU - Yin, Y. W. PY - 2015 DA - 2015// TI - The histone acetyltransferase GCN5 expression is elevated and regulated by c-Myc and E2F1 transcription factors in human colon cancer JO - Gene Expr VL - 16 UR - https://doi.org/10.3727/105221615X14399878166230 DO - 10.3727/105221615X14399878166230 ID - Yin2015 ER - TY - JOUR AU - Chen, L. PY - 2013 DA - 2013// TI - Lysine acetyltransferase GCN5 potentiates the growth of non-small cell lung cancer via promotion of E2F1, cyclin D1, and cyclin E1 expression JO - J Biol Chem VL - 288 UR - https://doi.org/10.1074/jbc.M113.458737 DO - 10.1074/jbc.M113.458737 ID - Chen2013 ER - TY - JOUR AU - Majaz, S. PY - 2016 DA - 2016// TI - Histone acetyl transferase GCN5 promotes human hepatocellular carcinoma progression by enhancing AIB1 expression JO - Cell Biosci VL - 6 UR - https://doi.org/10.1186/s13578-016-0114-6 DO - 10.1186/s13578-016-0114-6 ID - Majaz2016 ER - TY - JOUR AU - Liu, K. PY - 2015 DA - 2015// TI - GCN5 potentiates glioma proliferation and invasion via STAT3 and AKT signaling pathways JO - Int J Mol Sci VL - 16 UR - https://doi.org/10.3390/ijms160921897 DO - 10.3390/ijms160921897 ID - Liu2015 ER - TY - JOUR AU - Ge, Q. AU - Ai, Z. AU - Wen, S. AU - Ma, L. AU - Dai, M. AU - Liu, F. AU - Zhu, X. AU - Ding, W. AU - Yang, B. AU - Teng, Y. PY - 2017 DA - 2017// TI - Improved risk assessment by integrating up-regulated GCN5 with clinicopathological features in low-risk endometrial cancer JO - Int J Clin Exp Med VL - 10 ID - Ge2017 ER - TY - JOUR AU - Farria, A. T. AU - Mustachio, L. M. AU - Akdemir, Z. H. C. AU - Dent, S. Y. R. PY - 2019 DA - 2019// TI - GCN5 HAT inhibition reduces human Burkitt lymphoma cell survival through reduction of MYC target gene expression and impeding BCR signaling pathways JO - Oncotarget VL - 10 UR - https://doi.org/10.18632/oncotarget.27226 DO - 10.18632/oncotarget.27226 ID - Farria2019 ER - TY - JOUR AU - Patel, J. H. PY - 2004 DA - 2004// TI - The c-MYC oncoprotein is a substrate of the acetyltransferases hGCN5/PCAF and TIP60 JO - Mol Cell Biol VL - 24 UR - https://doi.org/10.1128/mcb.24.24.10826-10834.2004 DO - 10.1128/mcb.24.24.10826-10834.2004 ID - Patel2004 ER - TY - JOUR AU - Holmlund, T. AU - Lindberg, M. J. AU - Grander, D. AU - Wallberg, A. E. PY - 2013 DA - 2013// TI - GCN5 acetylates and regulates the stability of the oncoprotein E2A-PBX1 in acute lymphoblastic leukemia JO - Leukemia VL - 27 UR - https://doi.org/10.1038/leu.2012.265 DO - 10.1038/leu.2012.265 ID - Holmlund2013 ER - TY - JOUR AU - Zhao, L. AU - Pang, A. AU - Li, Y. PY - 2018 DA - 2018// TI - Function of GCN5 in the TGF-beta1-induced epithelial-to-mesenchymal transition in breast cancer JO - Oncol Lett VL - 16 UR - https://doi.org/10.3892/ol.2018.9134 DO - 10.3892/ol.2018.9134 ID - Zhao2018 ER - TY - JOUR AU - Zhao, M. PY - 2017 DA - 2017// TI - PCAF/GCN5-mediated acetylation of RPA1 promotes nucleotide excision repair JO - Cell Rep VL - 20 UR - https://doi.org/10.1016/j.celrep.2017.08.015 DO - 10.1016/j.celrep.2017.08.015 ID - Zhao2017 ER - TY - JOUR AU - Goodman, R. H. AU - Smolik, S. PY - 2000 DA - 2000// TI - CBP/p300 in cell growth, transformation, and development JO - Genes Dev VL - 14 ID - Goodman2000 ER - TY - JOUR AU - Iyer, N. G. AU - Ozdag, H. AU - Caldas, C. PY - 2004 DA - 2004// TI - p300/CBP and cancer JO - Oncogene VL - 23 UR - https://doi.org/10.1038/sj.onc.1207118 DO - 10.1038/sj.onc.1207118 ID - Iyer2004 ER - TY - JOUR AU - Guo, W. PY - 2014 DA - 2014// TI - Transcriptional coactivator CBP upregulates hTERT expression and tumor growth and predicts poor prognosis in human lung cancers JO - Oncotarget VL - 5 UR - https://doi.org/10.18632/oncotarget.2430 DO - 10.18632/oncotarget.2430 ID - Guo2014 ER - TY - JOUR AU - Ward, R. AU - Johnson, M. AU - Shridhar, V. AU - Deursen, J. AU - Couch, F. J. PY - 2005 DA - 2005// TI - CBP truncating mutations in ovarian cancer JO - J Med Genet VL - 42 UR - https://doi.org/10.1136/jmg.2004.025080 DO - 10.1136/jmg.2004.025080 ID - Ward2005 ER - TY - JOUR AU - Crowley, J. A. AU - Wang, Y. AU - Rapoport, A. P. AU - Ning, Y. PY - 2005 DA - 2005// TI - Detection of MOZ-CBP fusion in acute myeloid leukemia with 8;16 translocation JO - Leukemia VL - 19 UR - https://doi.org/10.1038/sj.leu.2403971 DO - 10.1038/sj.leu.2403971 ID - Crowley2005 ER - TY - JOUR AU - Ishihama, K. PY - 2007 DA - 2007// TI - Expression of HDAC1 and CBP/p300 in human colorectal carcinomas JO - J Clin Pathol VL - 60 UR - https://doi.org/10.1136/jcp.2005.029165 DO - 10.1136/jcp.2005.029165 ID - Ishihama2007 ER - TY - JOUR AU - Ring, A. PY - 2018 DA - 2018// TI - CBP/β-Catenin/FOXM1 is a novel therapeutic target in triple negative breast cancer JO - Cancers (Basel) VL - 10 UR - https://doi.org/10.3390/cancers10120525 DO - 10.3390/cancers10120525 ID - Ring2018 ER - TY - JOUR AU - Germaniuk-Kurowska, A. PY - 2007 DA - 2007// TI - Ada3 requirement for HAT recruitment to estrogen receptors and estrogen-dependent breast cancer cell proliferation JO - Cancer Res VL - 67 UR - https://doi.org/10.1158/0008-5472.can-07-2721 DO - 10.1158/0008-5472.can-07-2721 ID - Germaniuk-Kurowska2007 ER - TY - JOUR AU - Smith, C. L. AU - Onate, S. A. AU - Tsai, M. J. AU - O'Malley, B. W. PY - 1996 DA - 1996// TI - CREB binding protein acts synergistically with steroid receptor coactivator-1 to enhance steroid receptor-dependent transcription JO - Proc Natl Acad Sci USA VL - 93 UR - https://doi.org/10.1073/pnas.93.17.8884 DO - 10.1073/pnas.93.17.8884 ID - Smith1996 ER - TY - JOUR AU - Acevedo, M. L. AU - Kraus, W. L. PY - 2003 DA - 2003// TI - Mediator and p300/CBP-steroid receptor coactivator complexes have distinct roles, but function synergistically, during estrogen receptor alpha-dependent transcription with chromatin templates JO - Mol Cell Biol VL - 23 UR - https://doi.org/10.1128/mcb.23.1.335-348.2003 DO - 10.1128/mcb.23.1.335-348.2003 ID - Acevedo2003 ER - TY - JOUR AU - Chen, H. AU - Lin, R. J. AU - Xie, W. AU - Wilpitz, D. AU - Evans, R. M. PY - 1999 DA - 1999// TI - Regulation of hormone-induced histone hyperacetylation and gene activation via acetylation of an acetylase JO - Cell VL - 98 UR - https://doi.org/10.1016/s0092-8674(00)80054-9 DO - 10.1016/s0092-8674(00)80054-9 ID - Chen1999 ER - TY - JOUR AU - Jiang, M. PY - 2019 DA - 2019// TI - Small molecule nAS-E targeting cAMP response element binding protein (CREB) and CREB-binding protein interaction inhibits breast cancer bone metastasis JO - J Cell Mol Med VL - 23 UR - https://doi.org/10.1111/jcmm.14024 DO - 10.1111/jcmm.14024 ID - Jiang2019 ER - TY - JOUR AU - Malhotra, G. K. AU - Zhao, X. AU - Band, H. AU - Band, V. PY - 2010 DA - 2010// TI - Histological, molecular and functional subtypes of breast cancers JO - Cancer Biol Ther VL - 10 UR - https://doi.org/10.4161/cbt.10.10.13879 DO - 10.4161/cbt.10.10.13879 ID - Malhotra2010 ER - TY - JOUR AU - Pereira, B. PY - 2016 DA - 2016// TI - The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes JO - Nat Commun VL - 7 UR - https://doi.org/10.1038/ncomms11479 DO - 10.1038/ncomms11479 ID - Pereira2016 ER - TY - JOUR AU - Brewster, A. M. PY - 2008 DA - 2008// TI - Residual risk of breast cancer recurrence 5 years after adjuvant therapy JO - J Natl Cancer Inst VL - 100 UR - https://doi.org/10.1093/jnci/djn233 DO - 10.1093/jnci/djn233 ID - Brewster2008 ER - TY - JOUR AU - Harbeck, N. PY - 2019 DA - 2019// TI - Breast cancer JO - Nat Rev Dis Primers VL - 5 UR - https://doi.org/10.1038/s41572-019-0111-2 DO - 10.1038/s41572-019-0111-2 ID - Harbeck2019 ER - TY - JOUR AU - Legube, G. AU - Trouche, D. PY - 2003 DA - 2003// TI - Regulating histone acetyltransferases and deacetylases JO - EMBO Rep VL - 4 UR - https://doi.org/10.1038/sj.embor.embor941 DO - 10.1038/sj.embor.embor941 ID - Legube2003 ER - TY - STD TI - CBP loss confers risk of aggressive form of breast cancer. Cancer Biol Ther. 2005;4:1306. https://doi.org/10.4161/cbt.4.12.2326. ID - ref41 ER - TY - JOUR AU - Ring, A. PY - 2018 DA - 2018// TI - CBP/beta-Catenin/FOXM1 is a novel therapeutic target in triple negative breast cancer JO - Cancers (Basel) VL - 10 UR - https://doi.org/10.3390/cancers10120525 DO - 10.3390/cancers10120525 ID - Ring2018 ER - TY - JOUR AU - Xiao, X. S. PY - 2011 DA - 2011// TI - High expression of p300 in human breast cancer correlates with tumor recurrence and predicts adverse prognosis JO - Chin J Cancer Res VL - 23 UR - https://doi.org/10.1007/s11670-011-0201-5 DO - 10.1007/s11670-011-0201-5 ID - Xiao2011 ER - TY - JOUR AU - Kosti, I. AU - Jain, N. AU - Aran, D. AU - Butte, A. J. AU - Sirota, M. PY - 2016 DA - 2016// TI - Cross-tissue analysis of gene and protein expression in normal and cancer tissues JO - Sci Rep VL - 6 UR - https://doi.org/10.1038/srep24799 DO - 10.1038/srep24799 ID - Kosti2016 ER - TY - JOUR AU - Xie, Y. PY - 2020 DA - 2020// TI - Breast cancer gene expression datasets do not reflect the disease at the population level JO - NPJ Breast Cancer VL - 6 UR - https://doi.org/10.1038/s41523-020-00180-x DO - 10.1038/s41523-020-00180-x ID - Xie2020 ER - TY - JOUR AU - Lipinski, M. AU - Blanco, B. AU - Barco, A. PY - 2019 DA - 2019// TI - CBP/p300 in brain development and plasticity: disentangling the KAT's cradle JO - Curr Opin Neurobiol VL - 59 UR - https://doi.org/10.1016/j.conb.2019.01.023 DO - 10.1016/j.conb.2019.01.023 ID - Lipinski2019 ER - TY - JOUR AU - Dietze, E. C. PY - 2005 DA - 2005// TI - CREB-binding protein regulates apoptosis and growth of HMECs grown in reconstituted ECM via laminin-5 JO - J Cell Sci VL - 118 UR - https://doi.org/10.1242/jcs.02616 DO - 10.1242/jcs.02616 ID - Dietze2005 ER - TY - JOUR AU - Harnish, D. C. AU - Scicchitano, M. S. AU - Adelman, S. J. AU - Lyttle, C. R. AU - Karathanasis, S. K. PY - 2000 DA - 2000// TI - The role of CBP in estrogen receptor cross-talk with nuclear factor-kappaB in HepG2 cells JO - Endocrinology VL - 141 UR - https://doi.org/10.1210/endo.141.9.7646 DO - 10.1210/endo.141.9.7646 ID - Harnish2000 ER - TY - JOUR AU - Xu, B. PY - 2019 DA - 2019// TI - The LIM protein Ajuba recruits DBC1 and CBP/p300 to acetylate ERalpha and enhances ERalpha target gene expression in breast cancer cells JO - Nucleic Acids Res VL - 47 UR - https://doi.org/10.1093/nar/gky1306 DO - 10.1093/nar/gky1306 ID - Xu2019 ER - TY - JOUR AU - Boswell, K. A. AU - Wang, X. AU - Shah, M. V. AU - Aapro, M. S. PY - 2012 DA - 2012// TI - Disease burden and treatment outcomes in second-line therapy of patients with estrogen receptor-positive (ER+) advanced breast cancer: a review of the literature JO - Breast VL - 21 UR - https://doi.org/10.1016/j.breast.2012.09.005 DO - 10.1016/j.breast.2012.09.005 ID - Boswell2012 ER - TY - JOUR AU - Ryu, J. M. PY - 2018 DA - 2018// TI - Only estrogen receptor “positive” is not enough to predict the prognosis of breast cancer JO - Breast Cancer Res Treat VL - 172 UR - https://doi.org/10.1007/s10549-018-4948-y DO - 10.1007/s10549-018-4948-y ID - Ryu2018 ER - TY - JOUR AU - Dai, X. PY - 2015 DA - 2015// TI - Breast cancer intrinsic subtype classification, clinical use and future trends JO - Am J Cancer Res VL - 5 ID - Dai2015 ER - TY - JOUR AU - Yersal, O. AU - Barutca, S. PY - 2014 DA - 2014// TI - Biological subtypes of breast cancer: prognostic and therapeutic implications JO - World J Clin Oncol VL - 5 UR - https://doi.org/10.5306/wjco.v5.i3.412 DO - 10.5306/wjco.v5.i3.412 ID - Yersal2014 ER - TY - JOUR AU - Liu, Y. AU - Wang, D. L. AU - Chen, S. AU - Zhao, L. AU - Sun, F. L. PY - 2012 DA - 2012// TI - Oncogene Ras/phosphatidylinositol 3-kinase signaling targets histone H3 acetylation at lysine 56 JO - J Biol Chem VL - 287 UR - https://doi.org/10.1074/jbc.M112.367847 DO - 10.1074/jbc.M112.367847 ID - Liu2012 ER - TY - JOUR AU - Ramadan, W. S. PY - 2018 DA - 2018// TI - Interplay between epigenetics, expression of estrogen receptor-alpha, HER2/ERBB2 and Sensitivity of triple negative breast cancer cells to hormonal therapy JO - Cancers (Basel) VL - 11 UR - https://doi.org/10.3390/cancers11010013 DO - 10.3390/cancers11010013 ID - Ramadan2018 ER - TY - JOUR AU - Oberländer, M. PY - 2014 DA - 2014// TI - A 'waterfall' transfer-based workflow for improved quality of tissue microarray construction and processing in breast cancer research JO - Pathol Oncol Res VL - 20 UR - https://doi.org/10.1007/s12253-014-9752-3 DO - 10.1007/s12253-014-9752-3 ID - Oberländer2014 ER - TY - JOUR AU - Remmele, W. AU - Stegner, H. E. PY - 1987 DA - 1987// TI - Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue JO - Pathologe VL - 8 ID - Remmele1987 ER - TY - JOUR AU - Cornejo, K. M. AU - Kandil, D. AU - Khan, A. AU - Cosar, E. F. PY - 2014 DA - 2014// TI - Theranostic and molecular classification of breast cancer JO - Arch Pathol Lab Med VL - 138 UR - https://doi.org/10.5858/arpa.2012-0442-RA DO - 10.5858/arpa.2012-0442-RA ID - Cornejo2014 ER - TY - JOUR AU - Ogawa, Y. PY - 2004 DA - 2004// TI - Immunohistochemical assessment for estrogen receptor and progesterone receptor status in breast cancer: analysis for a cut-off point as the predictor for endocrine therapy JO - Breast Cancer VL - 11 UR - https://doi.org/10.1007/bf02984548 DO - 10.1007/bf02984548 ID - Ogawa2004 ER -